On August 8, 2022, Rob Schott, M.D., M.P.H., F.A.C.C., Senior Vice President, Head of Development of Sangamo Therapeutics, Inc. notified the Company of his resignation from this position and from his employment with the Company, with such resignation to be effective on August 19, 2022, in order to pursue a new opportunity. Dr. Schott's resignation is not due to any disagreement with the Company on any matter relating to the Company's operations, financial statements, internal controls, auditors, policies or practices. Effective August 19, 2022, Nathalie Dubois-Stringfellow, Ph.D., currently serving as Senior Vice President, Product Development and Management, will assume the role of Senior Vice President, Head of Development of the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.511 USD | +1.71% | -4.98% | -8.71% |
Mar. 22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
Mar. 14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.71% | 104M | |
+2.75% | 108B | |
+9.08% | 105B | |
-0.23% | 23.46B | |
-14.37% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-7.52% | 17.19B | |
+6.30% | 13.99B | |
+36.18% | 12.53B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc Announces Executive Changes